Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GALR3 | O60755 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12191370 | 0.95 | LMNA (0.41) | LMNAMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL11245129 | 0.94 | LMNA (0.36) | LMNAMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL28232410 | 0.89 | ALDH1A1 (0.41) | LMNAMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL4688117 | 0.87 | ALDH1A1 (0.46) | LMNAALDH1A1HSD17B10GALR3CHRM5 | |
| Hydrochloric Acid SCHEMBL4955070 | 0.85 | ALDH1A1 (0.43) | LMNAALDH1A1HSD17B10GALR3CHRM5 | |
| Edetic Acid SCHEMBL7899139 | 0.82 | TDP1 (0.45) | LMNAHSD17B10KDM4ECHRM2TSHR | |
| SCHEMBL9779164 | 0.81 | ALDH1A1 (0.42) | MEN1KMT2AALDH1A1 | |
| SCHEMBL20865657 | 0.81 | ALDH1A1 (0.46) | LMNAMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL7928706 | 0.80 | — | — | |
| SCHEMBL9778987 | 0.79 | ALDH1A1 (0.39) | LMNAALDH1A1HSD17B10GALR3CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200276108-A1 | PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | EPI HEALTH, LLC | 2020-09-03 | — | — | US | claimed |
| US-20200188517-A1 | PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE | EPI HEALTH, LLC | 2020-06-18 | — | — | US | claimed |
| US-20190029996-A1 | composition containing artesunate | ZHAO MING (US) | 2019-01-31 | — | — | US | claimed |
| US-20160279155-A1 | NOVEL FORMULATIONS | AEROMICS, INC. (US) | 2016-09-29 | — | — | US | claimed |
| EP-3065729-A2 | NOVEL FORMULATIONS | Aeromics, Inc. (US) | 2016-09-14 | — | — | EP | claimed |
| WO-2015069956-A2 | NOVEL FORMULATIONS | AEROMICS, LLC (US) | 2015-05-14 | — | — | WO | claimed |
| EP-2089429-B1 | PROCESS FOR PREPARING UNAGGREGATED ANTIBODY FC DOMAINS | JANSSEN BIOTECH INC (US) | 2014-11-26 | — | — | EP | claimed |
| US-8853371-B2 | Process for preparing unaggregated antibody Fc domains | JANSSEN BIOTECH, INC. (US) | 2014-10-07 | — | — | US | claimed |
| US-20130098775-A1 | Glucose biosensor with improved shelf life | NOVA BIOMEDICAL CORPORATION (US) | 2013-04-25 | — | — | US | claimed |
| WO-2013059534-A1 | GLUCOSE BIOSENSOR WITH IMPROVED SHELF LIFE | NOVA BIOMEDICAL CORPORATION (US) | 2013-04-25 | — | — | WO | claimed |
| US-7816527-B2 | Quinazoline-containing kits for labeling aldehyde or ketone moieties | Life Technologies Corporation (US) | 2010-10-19 | — | — | US | claimed |
| US-20090171072-A1 | Process for Preparing Unaggregated Antibody FC Domains | CENTOCOR ORTHO BIOTECH INC. | 2009-07-02 | — | — | US | claimed |
| EP-1097171-B1 | METHOD FOR PURIFYING HEMOGLOBIN | BIOPURE CORP (US) | 2006-12-06 | — | — | EP | claimed |
| EP-0432221-B1 | ONE-STEP IN SITU HYBRIDIZATION ASSAY | APROGENEX INC (US) | 1997-05-28 | — | — | EP | claimed |
| US-12496308-B2 | Methods of administering a pharmaceutically acceptable salt of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate | AEROMICS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4630545-A1 | METHOD FOR SEPARATING BETA-XYLOSIDASE ENZYME FROM AN ENZYME MIXTURE | IFP Energies nouvelles (FR) | 2025-10-15 | — | — | EP | disclosed |
| US-20250206765-A1 | CRYSTALS | AEROMICS, INC. (US) | 2025-06-26 | — | — | US | disclosed |
| EP-0380313-A2 | Field inversion electroblotting | EASTMAN KODAK COMPANY (US) | 1990-08-01 | — | — | EP | disclosed |
| EP-0365321-A2 | Electrophoresis apparatus | EASTMAN KODAK COMPANY (US) | 1990-04-25 | — | — | EP | disclosed |
| US-4205130-A | AFFINITY VHROMATORGAPHY, ISOELECTRIC FOCUSING | VIHKO PIRKKO | 1980-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206765-A1 | CRYSTALS | MTAP, PLCG2, PLCG1 | LMNA 3026/4885MEN1 2233/4885KMT2A 3403/4885 |
| US-12496308-B2 | Methods of administering a pharmaceutically acceptable salt of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate | SLC34A2, SLC20A2, SLC34A3 | LMNA 4513/4885MEN1 1917/4885KMT2A 3383/4885 |
| US-20200276108-A1 | PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | PDE3A, TREH, VEGFA | LMNA 2818/4885MEN1 3703/4885KMT2A 1761/4885 |
| US-20160279155-A1 | NOVEL FORMULATIONS | AQP1, AQP4, AQP3 | LMNA 3787/4885MEN1 1877/4885KMT2A 4121/4885 |
| US-20200188517-A1 | PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE | CUTA, KRT18, IL17A | LMNA 1439/4885MEN1 4119/4885KMT2A 3287/4885 |
| US-20190029996-A1 | composition containing artesunate | MTAP, PDF, GLS2 | LMNA 1482/4885MEN1 4110/4885KMT2A 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.